UroToday.com - In the online version of the FASEB Journal, Dr. Kelly and associates from Memorial Sloan-Kettering Cancer Center report that oncolytic therapy using HSV engineered to minimize neurotoxicity holds clinical promise. Herpes oncolytic vectors are effective gene transfer agents with attenuated toxicity to normal cells. These are replication competent viruses that have potent antitumor activity by inducing direct tumor cell lysis.